Search PubMed⌕ Search
Home/Archive/PubMed

PubMed · 16696213

[Obesity and immune function].

Nicolantonio D'Orazio
View original source ↗Export metadata ↓

Abstract

The perspective of obesity as a low grade systemic inflammatory condition has triggered a new interest on the many overlapping areas between this pathology and the immune system. White adipose tissue production of proteins related to the immune function has shown that many of these adipokines are implied in the ethiopathogenesis of some of the major metabolic diseases such as diabetes, hypertension, cardiovascular diseases, which share with obesity an important role in the Metabolic Syndrome. Besides, dysregulation of immune system may be present due to a dysregulation in the factors produced by adipose tissue. Weight loss through diet or surgery has proved to be beneficial for the recovery of the physiological levels of some of these pro-inflammatory molecules, but other studies are needed to clarify to which extent its possible to pursue risk reduction by this way.

Explore related subjects

AdiponectinAdipose TissueBariatric SurgeryDiet, ReducingHumansImmune SystemInflammationLeptinMetabolic SyndromeObesity, MorbidWeight LossJournal ArticleReview

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Nicolantonio D'Orazio. [Obesity and immune function].. https://pubmed.ncbi.nlm.nih.gov/16696213/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2007

The benefits of early intervention in obese diabetic patients with FBCx: a new dietary fibre.

BACKGROUND: Obesity and diabetes have become epidemic in the US. Dietary fibres have been reported to reduce the absorption of dietary fat, prevent weight gain, and reduce blood lipid levels. In the current double-blind study, obese patients with type 2 diabetes were recruited for a 3-month study to examine the health effects of a new dietary fibre, FBCx. METHODS: Sixty-six participants were recruited and were randomized into FBCx or placebo groups. They were instructed to take two 1-g tablets per fat-containing meal and not to change their eating patterns or daily routine. Three-day dietary records and fasting blood samples were collected prior to enrollment in the study and at the end of months 1, 2 and 3. RESULTS: Dietary records showed that some participants changed their eating patterns; therefore body weight data were adjusted according to energy intake. As a group, in the 30 days leading into the study, all participants experienced an average weight gain of 1.0 +/- 0.4 kg, while those in the placebo group continued to gain weight during the study, those in the FBCx group maintained their weight. Those in the FBCx group required more energy to maintain their body weight while those in the placebo group required less (p < 0.05). Participants with hypertriglyceridemia showed a reduction (-0.48 +/- 0.24 mmol/L, - 8.2%) in total cholesterol with FBCx, while those with placebo had an increase (0.24 +/- 0.21 mmol/L, 5.2%, p < 0.05). Adiponectin was increased in the FBCx but reduced in the placebo group (p < 0.05). CONCLUSIONS: FBCx has thus shown promising benefits in weight maintenance, a reduction of blood lipids and an increase in adiponectin levels. It can be easily incorporated into a diabetic management regimen.

Adiponectin↗
PubMed2006

Hepatic steatosis and insulin resistance are associated with serum imbalance of adiponectin/tumour necrosis factor-alpha in chronic hepatitis C patients.

BACKGROUND: Steatosis and insulin resistance (IR) have a pathogenic role in chronic hepatitis C (HCV). Adipocytokines balance modulates hepatic lipid content and IR. AIM: To evaluate serum adipocytokines and relationship with virological, histological and metabolic parameters in chronic HCV. METHODS: Adiponectin and tumour necrosis factor-alpha (TNF-alpha) levels, HCV genotypes, HCV-RNA, IR (HOMA-IR), body mass index and liver steatosis and fibrosis were assessed in 161 non-diabetic chronic HCV patients. RESULTS: Chronic HCV patients with steatosis showed lower serum adiponectin levels and higher levels of TNF-alpha, HOMA, alanine aminotransferase, gamma-glutamiltransferase and Histological Activity Index (HAI) and fibrosis scores. Low adiponectin levels were independently associated with grades of steatosis and HOMA-IR. Higher tumour necrosis factor-alpha levels were observed in patients with low adiponectin levels. The extension of steatosis was inversely correlated with adiponectin levels. A correlation between grade of steatosis with HOMA-IR and fibrosis was observed. HCV genotype 3-infected patients showed lower adiponectin levels than those with other genotypes. An independent predictor of low adiponectin levels in genotype 3 infection was the extension of steatosis. Liver fibrosis score was associated with steatosis, HAI and age. CONCLUSIONS: Chronic HCV patients with steatosis showed a serum adiponectin/TNF-alpha imbalance that is associated with IR. Reduced adiponectin levels may be involved in the pathogenesis of steatosis, which in turn accelerates progression of fibrosis in chronic HCV.

Adiponectin↗